Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression.
Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.
The primary objective of this study was to investigate the changes of the expression of T2DM susceptible genes (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) in participants (newly diagnosed T2DM patients and controls) after gene mutation.
Secondly, the expression differences of T2DM susceptible genes in T2DM patients with different genotypes were compared, and the relationship between the expression differences and clinicopathological characteristics of T2DM patients was analyzed.
Participants (newly diagnosed T2DM patients and healthy subjects) were screened from the department of endocrinology and health management center, whose fresh peripheral blood were collected. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected in the department of general surgery. The DNA genome was extracted for genotyping, and then the expression levels of T2DM related susceptibility genes under different genotypes were detected by ELISA kits, PCR, WB,HE staining, IHC staining, ect.
The basic information of T2DM patients was collected, including demographic characteristics, physiological and biochemical data.Then investigators further compared the differences in the expression of susceptible genes between newly diagnosed T2DM patients and controls.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comparison of T2DM susceptibility gene expression between newly diagnosed T2DM patients and controls | Experimental | To determine the effect of gene mutations on the susceptibility of T2DM by comparing the expression levels of T2DM susceptibility genes in newly diagnosed T2DM patients and controls. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs | Drug | Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups. |
| Measure | Description | Time Frame |
|---|---|---|
| Detection of T2DM susceptibility gene expression in newly diagnosed T2DM patients | To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of newly diagnosed T2DM patients and compared with those in healthy subjects. | 1 month after fresh sample collection |
| Detection of T2DM susceptibility gene expression in controls | To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of controls and compared with those in newly diagnosed T2DM patients. | 1 month after fresh sample collection |
| Correlation between T2DM susceptibility gene expression and clinicopathological features | Incidence of clinical pancreatic diseases under expression differences in T2DM susceptibility genes | 6 months after obtaining the clinicopathological results |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline BMI of newly diagnosed with T2DM patients with different genotypes | Baseline BMI of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline waist hip ratio (WHR) of newly diagnosed with T2DM patients with different genotypes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tao Wang, Ph.D | Contact | 13815344640 | misswt2011@126.com | |
| Xiaoxing Yin, Ph.D | Contact | 13605218523 | yinxx@xzmc.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China, Jiangsu, Department of Endocrinology | Recruiting | Xuzhou | 221006 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs | Drug | The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection. In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing. |
|
Baseline WHR of newly diagnosed with T2DM patients |
| 1 month of completion for individual screening |
| Baseline fasting plasma glucose (FPG) of newly diagnosed with T2DM patients with different genotypes | Baseline FPG of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline HbA1c of newly diagnosed with T2DM patients with different genotypes | Baseline HbA1c of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline TC of newly diagnosed with T2DM patients with different genotypes | Baseline TC of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline TG of newly diagnosed with T2DM patients with different genotypes | Baseline TG of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline HDL-C of newly diagnosed with T2DM patients with different genotypes | Baseline HDL-C of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline LDL-C of newly diagnosed with T2DM patients with different genotypes | Baseline LDL-C of newly diagnosed with T2DM patients | 1 month of completion for individual screening |
| Baseline BMI of controls with different genotypes | Baseline BMI of controls | 1 month of completion for individual screening |
| Baseline WHR of controls with different genotypes | Baseline WHR of controls | 1 month of completion for individual screening |
| Baseline FPG of controls with different genotypes | Baseline FPG of controls | 1 month of completion for individual screening |
| Baseline HbA1c of controls with different genotypes | Baseline HbA1c of controls | 1 month of completion for individual screening |
| Baseline TC of controls with different genotypes | Baseline TC of controls | 1 month of completion for individual screening |
| Baseline TG of controls with different genotypes | Baseline TG of controls | 1 month of completion for individual screening |
| Baseline HDL-C of controls with different genotypes | Baseline HDL-C of controls | 1 month of completion for individual screening |
| Baseline LDL-C of controls with different genotypes | Baseline LDL-C of controls | 1 month of completion for individual screening |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D020022 | Genetic Predisposition to Disease |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D004198 | Disease Susceptibility |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007004 | Hypoglycemic Agents |
| ID | Term |
|---|---|
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided